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Abstract 
Background: Cognitive impairment (CI) is a frequent symptom of multiple sclerosis (MS); its 
prevalence is reported to be 43-70%. It is one of the most important determinants of MS patients’ 
quality of life, as it is one of the main factors for MS patients becoming unemployed.  
Aim: We aimed to determine the prevalence of CI among the relapsing-remitting MS (RRMS) and 
clinically isolated syndrome (CIS) patients in Hungary, to evaluate the predicting factors of CI and to 
assess the differences between sexes and patients with different educational levels. 
Patients and methods: Five-hundred and fifty-three CIS and RRMS patients were enrolled to our 
study from three Hungarian MS centers. Age at screening, age at disease onset, disease duration, 
EDSS score, sex and educational levels were analyzed as socio-demographic factors. The BICAMS 
battery was used to assess their cognitive state, the BDI-II battery to assess depression. For statistical 
analysis, we utilized logistical regression, and used Fisher exact tests, chi-square tests and one-way 
ANOVA. 
Results: The mean age of our patients was 44.93±11.69 years, mean age at disease onset was 
31.95±10.01 years, the mean disease duration was 13.05±8.05 years and the median EDSS score 2.0 
(Range: 6.5, IQR:2.0) points. Three-hundred and sixteen (57.1%) patients had CI. Sex, educational 
level and EDSS score proved to be significant predictors of CI (OR: 2.71, p<0.001; OR: 1.94, p=0.023; 
OR: 0.47, p=0.003 respectively). CI was significantly (p<0.001) more frequent among men (70.1%) 
than women (52.0%). We found, that educational level and EDSS score were only a significant 
predicting factor among women. Thus, the prevalence of CI among women with college or university 
degree was significantly (p<0.001) less common (39.4%) than women with 12-15 years of education 
(57.4%) and women without a high school degree (66.7%). Also, we found that among women with 
higher EDSS score than 2 points, the prevalence of CI is 69.9% as compared to women with EDSS 
score between 0-2 points, where the prevalence is 42.8% (p<0.001). No such differences were 
observed among man.  
Discussion: Our prevalence data is similar to those reported in the literature (43-70%), and almost 
identical to the one assessment using the BICAMS battery. We found that men are more vulnerable 
to CI than women in MS, as was reported recently. We are the first to report however, that higher 
educational level and lower EDSS scores are only associated with better cognitive performance in 
women. 
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Introduction 
Cognitive impairment (CI) is a frequent and substantial symptom of multiple sclerosis (MS); studies 
report its prevalence to be 43-70% (Chiaravalloti and DeLuca, 2008). CI has a serious negative impact 
on the patients’ quality of life. Cognitively impaired patients are more likely to have reduced physical 
independence and competence in daily activities; to report impaired social lives and higher rates of 
divorce (DeLuca et al., 2015; Goverover et al., 2007; Rao et al., 1991b). Also it negatively affects the 
patients’ coping mechanism, medical adherence and rehabilitation potential (Bruce et al., 2010; 
Ehrensperger et al., 2008; Langdon and Thompson, 1999). It is indicated to be the strongest predictor 
of MS patients’ becoming unemployed  (Krause et al., 2013; Morrow et al., 2010). 
MS patients don’t suffer from global impairment of cognitive functions: the most frequently affected 
domains are information processing speed, visuospatial memory and verbal memory (Langdon, 
2011).  
CI can appear at any stage of the disease, even as early as the clinically isolated syndrome (CIS) and 
radiologically isolated syndrome (RIS) stages and affects patients regardless of their age or physical 
state (Amato et al., 2012; Glanz et al., 2007). Studies report CI to be a progressive consequence of MS 
with very low chance of improvement once it occurs (DeLuca et al., 2015). There are very little, and 
also conflicting data about the effect of disease modifying therapies (DMTs) on cognition in MS 
(Mattioli et al., 2015; Sundgren et al., 2016). There is evidence that cognitive dysfunction can appear 
as acute relapse, as described by Morrow et al (Morrow et al., 2011). Also, MS may present with 
primarily cognitive dysfunction with minimal or no other neurological domains involved (Calabrese et 
al., 2015).  Until now, no clinical characteristic was found to be predictive of developing or worsening 
cognitive impairment (Amato et al., 2001). 
The best biomarkers for CI in MS are provided by magnetic resonance imaging (MRI) data. There are 
several studies indicating that CI correlates with global brain atrophy and regional atrophy in the 
cerebral cortex, hippocampal region, thalamus and the basal ganglia (Brass et al., 2006; DeLuca et al., 
2015; Houtchens et al., 2007; Koenig et al., 2014; Morgen et al., 2006). Also the presence of gray 
matter lesions and the greater volume of white matter lesions – predominantly in the corpus 
callosum - are linked to the presence of cognitive impairment (Calabrese et al., 2007; Diker et al., 
2016; Rossi et al., 2012). Furthermore, there are evidences provided by diffusion tensor imaging (DTI) 
studies, that disconnection resulting from diffuse and non-lesional white matter damage contribute 
to cognitive dysfunction in MS, as well as dysfunction in the default mode network (DMN) (Bonavita 
et al., 2011; Dineen et al., 2009; Paul, 2016; Rocca et al., 2010).  
The large difference between the prevalence data are not surprising as the studies not only were 
conducted on different populations, but also used different methodology to determine cognitive 
dysfunction. Also, the screening of cognition can be very time-consuming and many times requires 
neuropsychologists and special tools. Therefore, a short, easily administered screening battery was 
needed in everyday practice. For this purpose, Langdon and colleagues created the “Brief 
International Cognitive Assessment for Multiple Sclerosis” (BICAMS) battery in 2011. The BICAMS is a 
short, easily administered, yet highly sensitive tool for measuring cognitive dysfunction in MS 
patients in the three most affected key areas: information processing speed, visuospatial memory 
and verbal memory (Langdon et al., 2012). It is comprised of three individual tests: the Symbol Digit 
Modalities Test (SDMT), a sensitive measuring tool for information processing speed, the first three 
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immediate recall trials of the Brief Visuospatial Memory Test Revised (BVMT-R), and the first five 
immediate recall trials of the California Verbal Learning Test (CVLT-II) (Langdon et al., 2012). 
The objectives of the present evaluation were to determine the prevalence of CI among the 
RRMS/CIS patients in Hungary, to assess the predictors of cognitive dysfunction and to evaluate the 
possible differences between sexes and patients with different educational levels. 
Patients and methods 
Patients 
We consecutively enrolled 553 (28 CIS and 525 RRMS) patients into our study beginning in February, 
2014, until November, 2015. Four-hundred and four was treated at the multiple sclerosis 
outpatients’ clinic of the Department of Neurology of the University of Szeged; 111 at the multiple 
sclerosis outpatients’ clinic of the Jahn Ferenc Dél-Pest Hospital in Budapest and 38 at the multiple 
sclerosis outpatients’ clinic of the Markhot Ferenc Hospital in Eger. One-hundred and fifty-seven 
patients were man, 396 women. They were classified into 3 categories depending on their 
educational level: the first group consisted of 123 patients, who had less than 12 years of education, 
indicating they did not obtain a high school degree; the second group, 209 patients either finished 
high school or after high school obtained some qualification but not a degree from college or 
university (12-15 years of education); the third group, 221 patients, had college or university level of 
graduation (16 or more years of education). Additionally, young patients currently enrolled to college 
or university were placed in the third group. Ninety patients received no disease modifying therapy 
(DMT); 169 patients received β-1-interferon (IFN), 129 patients glatiramer-acetate, 31 patients 
teriflunomide, 33 patients dimethyl-fumarate therapy; 56 patients were on natalizumab and 41 
patients on fingolimod. Additionally, 1-1 patient was involved in the daclizumab, the LINGO-1 and the 
siponimod clinical trials. 
All sociodemographic data on the patients including age, age at disease onset, disease duration and 
EDSS score were obtained from the Multiple Sclerosis Register in case of the center, or from the 
outpatient treatment reports.  
We included patients into the evaluation, if:  
1. Their age was 18 years or older.  
2. The first language was Hungarian.  
3. They were diagnosed with CIS or RRMS based on the revised McDonald’s criteria (Polman et 
al., 2011).  
4. They were in remission and did not receive steroid therapy for at least 30 days during the 
evaluation.  
5. Their EDSS score ranged from 0-6.5.  
We have excluded patients from the study: 
1. With secondary (SPMS) or primary progressive (PPMS) course of the disease.  
2. If they were undergoing acute infection or an acute relapse.  
3. If they were diagnosed with psychiatric or personality disorder as these have a fairly large co-
incidence with MS and can cause cognitive impairment (Marrie et al., 2015).  
4. If they had a history of chronic alcoholism as it can also worsen the cognitive state (Bernardin 
et al., 2014). 
5. If they had a history of drug abuse or dependence (Worley et al., 2014). 
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Methods 
We evaluated the patients’ cognitive state with the Hungarian version of the Brief International 
Cognitive Assessment for Multiple Sclerosis (BICAMS) questionnaire (Sandi et al., 2015). As no 
consensual threshold on CI for BICAMS has been proposed yet, we used the thresholds given in the 
manuals of the separate tests (-1.5 standard deviation [SD] below the average for SDMT; T-score 40 
or below for BVMT-R and CVLT-II). We identified patients as cognitively impaired whom had 
abnormal scores on one or more tests, a criterion proposed by Dusankova et al. in 2012 in their own 
BICAMS validation process (Dusankova et al., 2012).  
Depression can seriously worsen the cognitive function of patients; therefore, its evaluation is very 
important to get a clear picture on the patients’ cognitive state. We used the Beck Depression 
Inventory (BDI-II) to assess depression in our group of patients (Beck, 1996). All patients with a score 
of 13 or above were classified as depressed.  
Statistical analysis 
We utilized univariate logistic regression model to assess the predictors of CI. To assess the 
differences in the cognitive state and depression between the sexes and patients with different levels 
of education, we used Fisher’s exact test and chi-square tests, for assessing the differences between 
key clinical and demographic factors (age, age at disease onset, disease duration, EDSS score) we 
utilized one-way ANOVA.  
All procedures performed in studies involving human participants were in accordance with the 
ethical standards of the institutional and/or national research committee and with the 1964 Helsinki 
declaration and its later amendments or comparable ethical standards. Informed consent was 
obtained from all individual participants included in the study. Ethics approval for this research was 
obtained from the Ethics Committee of the University of Szeged (authorization number 127/2013). 
Results 
All 553 patients have been tested with the BICAMS battery while we have data on 437 patients’ BDI 
scores. The difference is due to either the patient did not fully complete the BDI questionnaire hence 
their score could not be reliably calculated or the patient did not consent to complete the BDI 
questionnaire. 
Demographics and clinical data 
The mean age of our patients was 44.93±11.69 years, mean age at disease onset was 31.95±10.01 
years, the mean disease duration was 13.05±8.05 years and the median EDSS score 2.0 (Range: 6.5, 
IQR:2.0) points. One-hundred and sixteen patients of the 437 (26.5%) were depressed, and only 17 
(4%) patients fell into the “severe” category. 
Table 1 shows the key clinical and demographic data on the sexes. There was no significant 
difference between the sexes in the rate of patients with different educational levels, disease 
duration, EDSS score and the rate of depression. Yet the men were approximately 4.5 years younger 
than the women and 3.5 years younger at the onset of MS.  These differences however are not 
considered to be clinically relevant (Table 1). Table 2 shows the demographic data on the different 
clinical forms. As expected, CIS patients have a considerably shorter disease duration and lower EDSS 
score as compared to RRMS patients. (Table 2). 
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Table 1: The comparison of clinical and demographic data of the male and female participants 
Clinical and demographic data Man Women Difference (p) 
Age (+SD) 40.83 (±11.35) 45.24 
(±11.49) 
4.39 (p<0.001)* 
Age at disease onset (+SD) 29.59 (±9.58) 32.88 (±9.91) 3.29 (p<0.001)* 
Disease duration (+SD) 12.21 (±8.06) 13.35 (±8.00) 1.14 (p=0.132) 
Median EDSS (Range; IQR) 2.0 (6.5; 2.0) 2.0 (6.5; 2.0) 0.0 (p=0.436) 
Education <12 
years 
42 (26.8%) 81 (20.5%) p=0.254 
12-15 
years 
54 (34.4%) 155 (39.1%) 
≥16 
years 
61 (38.9%) 160 (40.4%) 
Depression Present 31 (23.8%) 85 (27.7%) 3.9% (p=0.477) 
Not 
present 
99 (76.2%) 222 (72.3%) 
SD, Standard deviation; IQR, Interquartile range 
 
Table 2: The comparison of clinical and demographic data of the CIS and RRMS participants  
Clinical and demographic data CIS RRMS Difference (p) 
Age (+SD) 42.46 (±12.09) 44.91 
(±11.65) 
2.45 (p=0.308) 
Age at disease onset (+SD) 35.82 (±12.20) 31.74 (±9.75) 4.08 (p<0.037)* 
Disease duration (+SD) 5.44 (±4.94) 13.71 (±8.14) 8.27 (p<0.001)* 
Median EDSS (Range; IQR) 0.0 (2.0; 1.5) 2.0 (6.5; 2.0) 2.0 (p<0.001)* 
Depression Present 6 (17.8%) 110 (27.1%) 9.3% (p=0.231) 
Not 
present 
22 (82.2%) 299 (72.9%) 
CIS, clinically isolated syndrome; RRMS, relapsing-remitting multiple sclerosis; SD, Standard 
deviation; IQR, Interquartile range 
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Prevalence of cognitive impairment 
Three-hundred and sixteen (57.1%) of our patients had some level of CI. Two-hundred and thirty-one 
patients (41.7%) had impaired SDMT scores, 210 patients (38.0%) had impaired BVMT-R scores and 
75 patients (13.6%) had impaired CVLT-II results. Ninety-one patients (16.5%) had impaired scores 
solely on the SDMT screening, 66 patients (11.8%) only on the BVMT-R questionnaire, and 6 patients 
(1.1%) only on the CVLT-II assessment. Eighty-four patients (15.2%) performed impaired on both the 
SDMT and the BVMT-R tests, 9 (1.6%) patients on both the SDMT and CVLT-II tests, and 13 patients 
(2.4%) on both the BVMT-R and the CVLT-II screenings. Forty-seven patients (8.5%) had impaired 
scores on all three batteries (Figure 1). There was no difference between cognitively impaired and 
unimpaired patients regarding the clinical and demographic data. Of our CIS patients, 7 (25.0%) had 
some level of CI as compared to the 309 (58.8%) of the RRMS patients. This difference is significant 
(p=0.001). 
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Figure 1: The rate of cognitive impairment among Hungarian patients with multiple sclerosis in the 
different subtests of the BICAMS battery 
 
SDMT, Symbol Digit Modalities Test; BVMT-R, Brief Visuospatial Memory Test Revised; CVLT-II, 
California Verbal Learning Test 2nd Edition 
We performed a univariate logistic regression analysis to assess the possible predictors of CI. Of the 
evaluated clinical and demographic parameters, disease duration, age, age at disease onset, 
receiving DMTs and depression did not predict CI; however, sex, educational level and EDSS score 
were significant predictors (Table 3). The dichotomization of EDSS score was based on the median 
EDSS level, similarly as in the survey done by Patti et al (Patti et al., 2015). Men had almost threefold 
risk to develop CI than women, people without a high school degree developed a twofold higher 
chance of CI than people with college and university degree. Also, people with low EDSS scores (0-2 
points) have approximately half the risk than people with higher EDSS scores. 
Table 3: Univariate logistic regression analysis of the predictors of cognitive impairment 
Predictor OR 95%CI p-value 
Sex Man 2,71 1.66-4.41 <0.001 
Women 1,00     
Education <12 years 1,94 1.10-3.42 0.023 
12-15 years 1,32 0.81-2.13 0.261 
≥16 years 1,00     
EDSS 0-2 points 0,47 0.29-0.77 0.003 
>2 points 1,00     
OR, odds ratio; 95%CI, 95% confidence interval; EDSS, Expanded Disability Status Scale. 
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Considering the differences between the sexes, 70.1% of the man had some level of CI, while 52.0% 
of the women suffered from cognitive dysfunction. This difference is statistically significant 
(p<0.001). Men had a higher rate of abnormal scores in all three subtests of the BICAMS battery than 
women (SDMT: 55.4% vs. 36.4%, BVMT-R: 48.4% vs. 33.8%, CVLT-II: 21.7% vs. 10.4%; p<0.001). The 
prevalence of CI among patients without high school degree was 68.3%, among patients with 12-15 
years of education 60.8% and among patients with college or university degree was 48.0%, which 
significantly differed from the other two categories (p=0.001). Patients had a significantly higher rate 
of impaired scores on both the SDMT (53.7%, 41.6%, 35.3%; p=0.004) and the BVMT-R (48.0%, 
39.7%, 30.8%; p=0.006) assessments as the educational levels lowered, but there was no significant 
difference between the groups in the CVLT-II assessment (17.1%, 14.8%, 10.4%; p=0.178). 
Considering EDSS score, 49.7% of patients with EDSS scores between 0-2 points had CI, while 72.9% 
of those, who had higher EDSS scores (p<0.001). Patients with higher EDSS scores performed worse 
on all BICAMS subtests, than patients with lower EDSS score (SDMT: 55.2% vs. 35.4%, BVMT-R: 53.1% 
vs. 31.1%, CVLT-II: 20.3% vs. 10.2%; p<0.001). 
We combined the predictors, and assessed both sexes with logistic regression analysis. It revealed 
that beside their sex, there is no other significant predictor of CI for man. The prevalence of CI did 
not significantly differ in any educational groups, or the groups based on EDSS scores. The only 
significant difference was in the BVMT-R performance of different EDSS categories (Table 4). 
However, among women, we found that both the educational categories and the EDSS score is a 
significant predictor of CI. Women with 12-15 years of education had an OR of 1.79 (95%CI: 1.10-
2.92; p=0.021), while women without high school degree an even higher, OR of 2.46 (95%CI: 1.34-
4.52; p=0.004) as compared to women with a college or university degree. Regarding EDSS score, 
women with EDSS scores between 0-2 points had an OR of 0.40 (95%CI: 0.24-0.65; p<0.001) as 
compared to women with higher EDSS scores. This is reflected in the prevalence of CI: the higher the 
education, the lower the prevalence of CI is (66.7% for women without a high school degree, 57.4% 
for women with 12-15 years of education and 39.4% for women with college or university degree; 
p<0.001); while the prevalence of CI is 42.8% among women with EDSS scores between 0-2 points 
and 69.9% with higher EDSS scores (p<0.001). Women with higher EDSS performed worse an all 
three BICAMS subtests, while women with higher education performed significantly better on SDMT 
and BVMT-R assessments, but not on the CVLT-II screening (Table 5).  
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Table 4: The rate of cognitive impairment among man with different educational levels, different 
EDSS score categories. Both the combined prevalence and the prevalence on the individual 
subtests of BICAMS are shown.  
Predictor All 
domain 
p-
value 
SDMT p-
value 
BVMT-
R 
p-
value 
CVLT-II p-
value 
Education <12 
years 
71.4% 0.949 64.3% 0.227 47.6% 0.687 19.0% 0.641 
12-15 
years 
68.5% 57.4% 44.4% 25.9% 
≥16 
years 
70.5% 47.5% 52.5% 19.7% 
EDSS 0-2 
points 
66.7% 0.098 53.8% 0.405 40.9% 0.012* 19.4% 0.422 
>2 
points 
79.7% 61.0% 62.7% 25.4% 
EDSS, Expanded Disability Status Scale; SDMT, Symbol Digit Modalities Test; BVMT-R, Brief 
Visuospatial Memory Test Revised; CVLT-II, California Verbal Learning Test 2nd Edition 
*significant on the level of p<0.05 
 
Table 5: The rate of cognitive impairment among woman with different educational levels, 
different EDSS score categories. Both the combined prevalence and the prevalence on the 
individual subtests of BICAMS are shown. 
Predictor All 
domain 
p-value SDMT p-value BVMT-
R 
p-value CVLT-II p-value 
Education <12 
years 
66.7% <0.001 48.1% 0.030 48.1% <0.001 16.0% 0.083 
12-15 
years 
57.4% 36.1% 38.1% 11.0% 
≥16 
years 
39.4% 30.6% 22.5% 6.9% 
EDSS 0-2 
points 
42.8% <0.001 27.9% <0.001 27.1% <0.001 6.6% 0.001 
>2 
points 
69.9% 52.6% 48.9% 18.0% 
EDSS, Expanded Disability Status Scale; SDMT, Symbol Digit Modalities Test; BVMT-R, Brief 
Visuospatial Memory Test Revised; CVLT-II, California Verbal Learning Test 2nd Edition 
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Discussion 
The prevalence of CI is 43-70% among patients with MS according to different studies dedicated to 
the topic (Chiaravalloti and DeLuca, 2008). As these evaluations were conducted with very different 
methodologies, these great differences between the results are not surprising: some assessments 
were conducted by assessing one domain only (with SDMT for example), other studies used complex 
neuropsychological examinations such as Rao’s Brief Repeatable Battery (Morrow et al., 2010; Rao et 
al., 1991a). Until 2011, there wasn’t any consensual, easily administered and scored, yet sensitive 
method to measure cognitive dysfunction in patients with MS. This changed with the introduction of 
the BICAMS battery by Langdon et al (Langdon et al., 2012). To our best knowledge, there has been 
only one prevalence data published to date, using the BICAMS battery: Dusankova et al found the 
prevalence of CI in the Czech MS population to be 55% in 2012 (Dusankova et al., 2012). We found 
the prevalence of CI to be 57.1% in Hungary, which is very similar to their findings, and well within 
the wide range of results published in other evaluations. Yet, our examination was carried out in an 
almost double-sized, homogenous population in contrast to the Czech assessment in which PPMS 
and SPMS patients also participated. As we know that CI occurs more often in the progressive forms 
of the disease, we hypothesize that our almost identical prevalence data is due to the larger, 
homogenous sample-size and would have been even higher if progressive patients were to be 
included. Yet, as to date, we only have therapy for RRMS, we believe that the appearance of CI in 
RRMS patients can have therapeutic consequences in the near future.  
We detected that information processing speed is the most vulnerable cognitive domain in 
Hungarian MS patients (41.7%), followed by visuospatial memory (37.8%). Verbal memory seems to 
be less affected than the other two domains (13.6%). These results are not surprising as other studies 
demonstrated similar tendencies to various degrees (Chiaravalloti and DeLuca, 2008). 
We found sex, education and EDSS score to be significant predictors of CI. This is in agreement with 
previous studies (Amato et al., 2006; Bonnet et al., 2006; DeLuca et al., 2015). We found no 
association between age at onset, disease duration and cognitive dysfunction. Earlier assessments 
were controversial on this matter: some studies found association with these factors, most, on the 
other hand, did not (Amato et al., 2012; DeLuca et al., 2015; Patti et al., 2015). This can partially be 
explained by the different sample sizes and methodologies of these assessments, but this should be 
evaluated further to get a clear picture. Also, we note, that the dichotomization of the EDSS score at 
the low level of 2 points might seem to be strange. Yet, we chose the median EDSS level for the 
differentiation, like the earlier study in Italy (Patti et al., 2015). In 2013, it was shown that in 
Csongrád-County, Hungary, 92% of RRMS patients have an EDSS score between 0-4 points, with a 
mean EDSS score of approximately 2 points, so our results are completely in line with this earlier 
report and warrant the choice of dichotomization at our chosen level (Zsiros et al., 2014). Our results 
imply that not the disease duration, rather the activity of the disease might be an important factor in 
developing CI, yet this is merely a speculative explanation and should be evaluated further in the 
future. Depression was not a significant factor, despite that it is linked to CI. Yet, it was also 
established, that mainly moderate to severe levels of depression have a significant impact on 
cognitive functioning (Siegert and Abernethy, 2005). In our sample, the majority of depressed 
patients fell into the mild category, so this might explain our results. In our assessment, men were 
more vulnerable to cognitive dysfunction (70.1%) than women (52.0%). Men showed higher 
prevalence rate of cognitive dysfunction in all three subtests of the BICAMS battery than women. 
Yet, there were no other significant predictors for cognitive dysfunction for men. There are only a 
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few studies that assessed sex differences in MS patients, and however they showed similar 
differences in prevalence, to our best knowledge, no other study found that education and EDSS are 
restricted to women as a predicting factor (DeLuca et al., 2015; Patti et al., 2015).  
The reason behind sex differences in cognitive functions is not well understood. Certain kind of 
genetic variables were assessed as factors in developing more serious cognitive dysfunction. It was 
established that the more frequent presence of the Apo-E ε4 allele in men led to more severe CI as 
compared to women (Savettieri et al., 2004). Also the role of sex hormones was implied: in 
particular, the possible protective effect of estrogens on cognitive function can partly explain these 
differences, as this protective effect has been already reported in other neurodegenerative 
conditions, most notably in Alzheimer’s and Parkinson’s disease (Bove et al., 2014; Miller and Cronin-
Golomb, 2010). Though, as we did not evaluate the genetic polymorphisms of our patients, these are 
merely speculative explanations, thus these differences can warrant further investigation into the 
link between genetics and cognitive functions. Our results also show that among women, the 
prevalence of CI is significantly lower among the highly educated and patients with lower EDSS 
scores. These findings are in line with previous assessments that showed EDSS might be a predictor 
of CI and also that higher cognitive reserve associated with higher educational levels is a protective 
factor against cognitive decline (Amato et al., 2006; Sumowski et al., 2014; Whalley et al., 2004). Yet, 
to our best knowledge, no assessment found that this only occurs in women. The reason behind this 
surprising finding can be partly explained by MRI assessments. It was demonstrated that MS patients 
suffer a faster rate of brain atrophy: and not only was the global atrophy rate higher, but several 
different structures (hippocampus, thalamus, basal ganglia) associated with memory show a higher 
rate of atrophy (Brass et al., 2006; DeLuca et al., 2015; Houtchens et al., 2007; Koenig et al., 2014; 
Morgen et al., 2006). Also, Király et al showed that brain atrophy is faster in healthy men than in 
healthy women (Kiraly et al., 2015). It is possible, that the accelerated atrophy in MS patients 
combined with the already faster atrophy rate in men results in the faster disappearance of cognitive 
reserve thus eliminating it as a protective factor. An important factor to consider can be, that male 
sex itself was shown to be a predictor for worse prognosis in MS patients (Weinshenker et al., 1991). 
Seemingly, this applies to the cognitive domain as well. 
The prevalence of CI among CIS patients was 25.0%, similarly to earlier reported findings (Hyncicova 
et al., 2017). Sadly, as we could only recruit 28 patients with CIS to our study, we could not make a 
similar, in depth analysis of the differences created by other factors as with our RRMS patients, due 
to the low number of participants in that group. Also, the problem caused by the low number of 
patients is apparent in the difference between their age at disease onset: it was almost 4 years 
higher than in RRMS patients, yet otherwise the disease duration was much shorter and the EDSS 
scores much lower, as expected. As sadly, many of the younger CIS patients declined to participate in 
the study, this difference is mainly caused by these biases. 
As conclusion, we can state that CI is a frequent yet under-diagnosed symptom of MS. Man are more 
susceptible to cognitive decline than women are. While higher education and lower EDSS scores 
seems to be a protective factor in women, apparently, it is not in men. This is possibly caused by the 
faster elimination of cognitive reserve by a higher rate of brain atrophy in men. To our best 
knowledge, we are the first to demonstrate this kind of difference between sexes in MS patients.  
We confirmed a fairly high prevalence of CI among CIS and RRMS patients who were young, active 
and in relatively good physical condition. This shows that despite a patient may seem to be 
symptom-free during a physical examination, the disease can still be active. Therefore, we believe 
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that the routine screening of the cognitive state and the detection of CI is highly important because it 
can help to decide on the best therapy for MS patients. 
The limitation of our study lies in its design: it is an epidemiological survey with no neuroimaging or 
genetical analysis included, therefore the explanation of the demonstrated differences and results 
are hypothetical. Possibly more in depth psychological assessments should be considered to assess 
the sex differences further. The next stages of this evaluation should be the inclusion of 
neuroimaging and possibly genetic factors to analyze beside the clinical and demographic data, as 
well as the follow-up of the patients in longer, longitudinal studies.  
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